{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:39:38Z","timestamp":1792802378803,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013986","name":"British Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013986","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>As neglected tropical disease programs rely on participation in rounds of mass drug administration (MDA), there is concern that individuals who have never been treated could contribute to ongoing transmission, posing a barrier to elimination. Previous research has suggested that the size and characteristics of the never-treated population may be important but have not been sufficiently explored. To address this critical knowledge gap, four meetings were held from December 2020 to May 2021 to compile expert knowledge on never treatment in lymphatic filariasis (LF) MDA programs. The meetings explored four questions: the number and proportion of people never treated, their sociodemographic characteristics, their infection status and the reasons why they were not treated. Meeting discussions noted key issues requiring further exploration, including how to standardize measurement of the never treated, adapt and use existing tools to capture never-treated data and ensure representation of never-treated people in data collection. Recognizing that patterns of never treatment are situation specific, participants noted measurement should be quick, inexpensive and focused on local solutions. Furthermore, programs should use existing data to generate mathematical models to understand what levels of never treatment may compromise LF elimination goals or trigger programmatic action.<\/jats:p>","DOI":"10.1093\/inthealth\/ihad091","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:57:56Z","timestamp":1697543876000},"page":"479-486","source":"Crossref","is-referenced-by-count":15,"title":["Persons \u2018never treated\u2019 in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020\u20132021"],"prefix":"10.1093","volume":"16","author":[{"given":"Molly A","family":"Brady","sequence":"first","affiliation":[{"name":"Department of Global Health, RTI International , Washington, DC 20008 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Toubali","sequence":"additional","affiliation":[{"name":"Neglected Tropical Diseases Division, Office of Infectious Disease, Bureau for Global Health, United States Agency for International Development , Washington, DC 20547 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Global Health, RTI International , Washington, DC 20008 , USA"},{"name":"Georgetown University , Washington , DC 20057 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Long","sequence":"additional","affiliation":[{"name":"Neglected Tropical Diseases Support Center, Task Force for Global Health , Decatur, GA 30030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Worrell","sequence":"additional","affiliation":[{"name":"Division of Parasitic Diseases and Malaria, U.S. Centers for Disease Control and Prevention , Atlanta, GA 30329 , USA"},{"name":"Department of Epidemiology, Swiss Tropical and Public Health Institute , Basel \u00a0 4051 , Switzerland"},{"name":"Faculty of Science, University of Basel , Basel \u00a0 4001 , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapa","family":"Ramaiah","sequence":"additional","affiliation":[{"name":"Consultant, Lymphatic Filariasis Epidemiologist , Pondicherry , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Graves","sequence":"additional","affiliation":[{"name":"College of Public Health, Medical and Veterinary Sciences and WHO Collaborating Centre for Vector-Borne and Neglected Tropical Diseases, James Cook University , Nguma-bada Campus, Cairns, QLD 4870 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5962-4238","authenticated-orcid":false,"given":"T Deirdre","family":"Hollingsworth","sequence":"additional","affiliation":[{"name":"Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford , Oxford, OX3\u00a07LF , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Kelly-Hope","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , Pembroke Place, Liverpool , L3\u00a05QA, UK"},{"name":"University of Liverpool, Institute of Infection , Veterinary and Ecological Sciences, Brownlow Hill, Liverpool, L2\u00a05RF , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Stukel","sequence":"additional","affiliation":[{"name":"Act to End Neglected Tropical Diseases West, Department of Global Health and Population , FHI 360, Washington, DC 20009 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupendra","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Bill and Melinda Gates Foundation, India Country Office , New Delhi 110067 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna Rubin","family":"Means","sequence":"additional","affiliation":[{"name":"Department of Global Health, University of Washington , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultani Hadley","family":"Matendechero","sequence":"additional","affiliation":[{"name":"Kenya National Public Health Institute , PO Box 30016-00100, GPO Nairobi , Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-1577","authenticated-orcid":false,"given":"Alison","family":"Krentel","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, University of Ottawa , 600 Peter Morand Drive, Ottawa, ON K1G\u00a05Z3 , Canada"},{"name":"Bruy\u00e8re Research Institute , Ottawa , ON K1N\u00a05C8 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"2024090511115819500_bib1","volume-title":"Ending the neglect to attain the Sustainable Development Goals: a roadmap for neglected tropical disease 2021\u20132030","author":"World Health Organization","year":"2020"},{"issue":"12","key":"2024090511115819500_bib2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.trstmh.2011.08.013","article-title":"Preventive chemotherapy in human helminthiasis: theoretical and operational aspects","volume":"105","author":"Gabrielli","year":"2011","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024090511115819500_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.epidem.2017.02.002","article-title":"Measuring and modelling the effects of systematic non-adherence to mass drug administration","volume":"18","author":"Dyson","year":"2017","journal-title":"Epidemics"},{"issue":"11","key":"2024090511115819500_bib4","doi-asserted-by":"crossref","first-page":"e1418","DOI":"10.1016\/S2214-109X(20)30344-2","article-title":"Patterns of individual non-treatment during multiple rounds of mass drug administration for control of soil-transmitted helminths in the TUMIKIA trial, Kenya: a secondary longitudinal analysis","volume":"8","author":"Oswald","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"Suppl 4","key":"2024090511115819500_bib5","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/cid\/ciy003","article-title":"Are alternative strategies required to accelerate the global elimination of lymphatic filariasis? Insights from mathematical models","volume":"66","author":"Stolk","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024090511115819500_bib6","article-title":"Transforming our world: the 2030 Agenda for Sustainable Development","author":"United Nations","year":"2015"},{"key":"2024090511115819500_bib7","article-title":"Tracking universal health coverage: first global monitoring report","author":"World Health Organization, World Bank","year":"2015"},{"key":"2024090511115819500_bib8","author":"World Health Organization","year":"2019","journal-title":"Preventive chemotherapy: tools for improving the quality of reported data and information. A field manual for implementation"},{"key":"2024090511115819500_bib9","volume-title":"Global programme to eliminate lymphatic filariasis: monitoring and epidemiological assessment of mass drug administration","author":"World Health Organization","year":"2011"},{"key":"2024090511115819500_bib10","author":"World Health Organization","year":"2010","journal-title":"Monitoring drug coverage for preventive chemotherapy"},{"issue":"6","key":"2024090511115819500_bib11","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4269\/ajtmh.2007.77.1069","article-title":"The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt","volume":"77","author":"El-Setouhy","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"2024090511115819500_bib12","doi-asserted-by":"crossref","first-page":"e0005027","DOI":"10.1371\/journal.pntd.0005027","article-title":"Improving coverage and compliance for mass drug administration for the elimination of LF in two \u2018endgame\u2019 districts in Indonesia using micronarrative surveys","volume":"10","author":"Krentel","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2024090511115819500_bib13","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1371\/journal.pntd.0000443","article-title":"Assessing the impact of a missed mass drug administration in Haiti","volume":"3","author":"Won","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"41","key":"2024090511115819500_bib14","first-page":"497","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2020","volume":"96","author":"World Health Organization","year":"2021","journal-title":"Wkly Epidemiol Rec"},{"issue":"9","key":"2024090511115819500_bib15","doi-asserted-by":"crossref","first-page":"e0009596","DOI":"10.1371\/journal.pntd.0009596","article-title":"Assessing factors influencing communities\u2019 acceptability of mass drug administration for the elimination of lymphatic filariasis in Guyana","volume":"15","author":"Niles","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"2024090511115819500_bib16","doi-asserted-by":"crossref","first-page":"e0006944","DOI":"10.1371\/journal.pntd.0006944","article-title":"The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar","volume":"12","author":"Dickson","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"2024090511115819500_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13071-017-2206-5","article-title":"The importance of patient compliance in repeated rounds of mass drug administration (MDA) for the elimination of intestinal helminth transmission","volume":"10","author":"Farrell","year":"2017","journal-title":"Parasit Vectors"},{"issue":"11","key":"2024090511115819500_bib18","doi-asserted-by":"crossref","first-page":"e0005027","DOI":"10.1371\/journal.pntd.0005027","article-title":"Improving coverage and compliance in mass drug administration for the elimination of LF in two \u2018endgame\u2019 districts in Indonesia using micronarrative surveys","volume":"10","author":"Krentel","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"2024090511115819500_bib19","doi-asserted-by":"crossref","first-page":"e2447","DOI":"10.1371\/journal.pntd.0002447","article-title":"A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis","volume":"7","author":"Krentel","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"2024090511115819500_bib20","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1371\/journal.pntd.0000640","article-title":"A community-based study of factors associated with continuing transmission of lymphatic filariasis in Leogane, Haiti","volume":"4","author":"Boyd","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"2024090511115819500_bib21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-3156.2006.01626.x","article-title":"Participation in three consecutive mass drug administrations in Leogane, Haiti","volume":"11","author":"Mathieu","year":"2006","journal-title":"Trop Med Int Health"},{"issue":"3","key":"2024090511115819500_bib22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1179\/136485905X29666","article-title":"Pattern of community compliance with spaced, single-dose, mass administrations of diethylcarbamazine or ivermectin, for the elimination of lymphatic filariasis from rural areas of southern India","volume":"99","author":"Vanamail","year":"2005","journal-title":"Ann Trop Med Parasitol"},{"issue":"43","key":"2024090511115819500_bib23","first-page":"509","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2019","volume":"99","author":"World Health Organization","year":"2020","journal-title":"Wkly Epidemiol Rec"},{"key":"2024090511115819500_bib24","volume-title":"Compliance with therapeutic regimens","author":"Sackett","year":"1976"},{"issue":"2","key":"2024090511115819500_bib25","first-page":"117","article-title":"An overview of the common methods used to measure treatment adherence","volume":"92","author":"Anghel","year":"2019","journal-title":"Med Pharm Rep"},{"issue":"4","key":"2024090511115819500_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2125.2007.02893.x","article-title":"Compliance, concordance, adherence","volume":"63","author":"Aronson","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"2024090511115819500_bib27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/bjsports-2015-095192","article-title":"\u2018Compliance\u2019 versus \u2018adherence\u2019 in sport injury prevention: why definition matters","volume":"50","author":"McKay","year":"2016","journal-title":"Br J Sports Med"},{"key":"2024090511115819500_bib28","article-title":"Forms for data collection at the peripheral level \u2013 Register","author":"World Health Organization"},{"key":"2024090511115819500_bib29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41182-017-0063-8","article-title":"Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration","volume":"45","author":"Coutts","year":"2017","journal-title":"Trop Med Health"},{"key":"2024090511115819500_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13071-020-3996-4","article-title":"Demographic, socioeconomic and disease knowledge factors, but not population mobility, associated with lymphatic filariasis infection in adult workers in American Samoa in 2014","volume":"13","author":"Graves","year":"2020","journal-title":"Parasit Vectors"},{"issue":"12","key":"2024090511115819500_bib31","doi-asserted-by":"crossref","first-page":"e0008916","DOI":"10.1371\/journal.pntd.0008916","article-title":"Potential strategies for strengthening surveillance of lymphatic filariasis in American Samoa after mass drug administration: reducing \u2018number needed to test\u2019 by targeting older age groups, hotspots, and household members of infected persons","volume":"14","author":"Lau","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"2024090511115819500_bib32","doi-asserted-by":"crossref","first-page":"e0008854","DOI":"10.1371\/journal.pntd.0008854","article-title":"A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018","volume":"14","author":"Willis","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"2024090511115819500_bib33","first-page":"e0009002","article-title":"A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis","volume":"15","author":"Krentel","year":"2021","journal-title":"PLoS Med"},{"issue":"1","key":"2024090511115819500_bib34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12889-017-4414-5","article-title":"A systematic review of factors that shape implementation of mass drug administration for lymphatic filariasis in sub-Saharan Africa","volume":"17","author":"Silumbwe","year":"2017","journal-title":"BMC Public Health"},{"key":"2024090511115819500_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13071-016-1311-1","article-title":"Compliance with anthelmintic treatment in the neglected tropical diseases control programmes: a systematic review","volume":"9","author":"Shuford","year":"2016","journal-title":"Parasit Vectors"},{"issue":"6","key":"2024090511115819500_bib36","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4269\/ajtmh.2007.77.1069","article-title":"The effect of compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt","volume":"77","author":"Setouhy","year":"2007","journal-title":"Am Soc Trop Med Hyg"},{"issue":"1","key":"2024090511115819500_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13071-021-04583-y","article-title":"Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar","volume":"14","author":"Dickson","year":"2021","journal-title":"Parasit Vectors"},{"issue":"1","key":"2024090511115819500_bib38","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1093\/cid\/ciaa1232","article-title":"Results from two cohort studies in central Africa show that clearance of Wuchereria bancrofti infection after repeated rounds of mass drug administration with albendazole alone is closely linked to individual adherence","volume":"73","author":"Campillo","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"20","key":"2024090511115819500_bib39","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMc1914262","article-title":"Single-dose triple-drug therapy for Wuchereria bancrofti\u20145-year follow-up","volume":"382","author":"King","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2024090511115819500_bib40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4269\/ajtmh.21-0817","article-title":"Proxy responses for mass drug administration coverage surveys: the trends and biases when others are allowed to respond","volume":"106","author":"Jose","year":"2021","journal-title":"Am J Trop Med Hyg"}],"container-title":["International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/inthealth\/article-pdf\/16\/5\/479\/59024440\/ihad091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/inthealth\/article-pdf\/16\/5\/479\/59024440\/ihad091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T22:58:42Z","timestamp":1725577122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/inthealth\/article\/16\/5\/479\/7319430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,10,17]]},"published-print":{"date-parts":[[2024,9,5]]}},"URL":"https:\/\/doi.org\/10.1093\/inthealth\/ihad091","relation":{},"ISSN":["1876-3413","1876-3405"],"issn-type":[{"value":"1876-3413","type":"print"},{"value":"1876-3405","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2023,10,17]]}}}